Skip to main content

Latest Articles

Latest Articles

Showing 9 / 1088 Ozempic articles

Big Food Invests Millions in Rebrands as GLP-1 Drugs Reshape Demand
GLP-1 Medications

Big Food Invests Millions in Rebrands as GLP-1 Drugs Reshape Demand

Global food giants like PepsiCo and Coca-Cola are ramping up investments in rebranded, protein-rich products as GLP-1 drugs suppress appetite and alter eating habits across 20% of U.S. households. With potential $12 billion in lost snack sales over the next decade, companies are shifting to smaller portions and nutrient-dense options. This adaptation highlights the lasting ripple effects of obesity medications on the food industry.

Shotlee··5 min read
GLP-1s Show Promise in MS, But More Rigorous Research Needed
Multiple Sclerosis

GLP-1s Show Promise in MS, But More Rigorous Research Needed

GLP-1 receptor agonists, originally developed for diabetes, are gaining attention for potential benefits in multiple sclerosis (MS) due to their effects on the brain and metabolic health. Expert Afsaneh Shirani, MD, highlighted promising studies at ACTRIMS, including weight loss and minimal relapses, but stressed the need for more rigorous trials. Key challenges like biomarkers, patient selection, and access remain.

Shotlee··6 min read